Deciphera Pharms patents expiration
1. Qinlock patents expiration
Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8188113 | DECIPHERA PHARMS | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jul, 2030
(6 years from now) | |
| US8461179 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
May, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48731 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(8 years from now) | |
| US8940756 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(8 years from now) | |
| US11529336 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11344536 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11576904 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11433056 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US10966966 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11426390 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11534432 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11266635 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11813251 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11850241 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11576903 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(16 years from now) | |
| US11395818 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11801237 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(16 years from now) | |
| US11844788 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11612591 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11185535 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(16 years from now) | |
| US11793795 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11850240 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11779572 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Oct, 2042
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2025 |
| Orphan Drug Exclusivity(ODE-298) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: 15 May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: Treatment of gastrointestinal stromal tumor; Treatment of gastrointestinal stromal tumors; Treatment of gastrointestinal stromal tumors in patients suffering from a grade 3 adverse reaction while bein...
Dosage: TABLET;ORAL
More Information on Dosage
QINLOCK family patents
